Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
LSD1
MAO
NEPC
epigenetics
mCRPC
neuroendocrine
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
15 Apr 2024
15 Apr 2024
Historique:
received:
26
02
2024
accepted:
26
03
2024
medline:
15
4
2024
pubmed:
15
4
2024
entrez:
15
4
2024
Statut:
aheadofprint
Résumé
Lysine-specific demethylase 1 (LSD1) is emerging as a critical mediator of tumor progression in metastatic castration-resistant prostate cancer (mCRPC). Neuroendocrine prostate cancer (NEPC) is increasingly recognized as an adaptive mechanism of resistance in mCRPC patients failing androgen receptor axis-targeted therapies. Safe and effective LSD1 inhibitors are necessary to determine antitumor response in prostate cancer models. For this reason, we characterize the LSD1 inhibitor bomedemstat to assess its clinical potential in NEPC as well as other mCRPC pathological subtypes. Bomedemstat was characterized via crystallization, flavine adenine dinucleotide spectrophotometry, and enzyme kinetics. On-target effects were assessed in relevant prostate cancer cell models by measuring proliferation and H3K4 methylation using western blot analysis. In vivo, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of bomedemstat are also described. Structural, biochemical, and PK/PD properties of bomedemstat, an irreversible, orally-bioavailable inhibitor of LSD1 are reported. Our data demonstrate bomedemstat has >2500-fold greater specificity for LSD1 over monoamine oxidase (MAO)-A and -B. Bomedemstat also demonstrates activity against several models of advanced CRPC, including NEPC patient-derived xenografts. Significant intra-tumoral accumulation of orally-administered bomedemstat is measured with micromolar levels achieved in vivo (1.2 ± 0.45 µM at the 7.5 mg/kg dose and 3.76 ± 0.43 µM at the 15 mg/kg dose). Daily oral dosing of bomedemstat at 40 mg/kg/day is well-tolerated, with on-target thrombocytopenia observed that is rapidly reversible following treatment cessation. Bomedemstat provides enhanced specificity against LSD1, as revealed by structural and biochemical data. PK/PD data display an overall safety profile with manageable side effects resulting from LSD1 inhibition using bomedemstat in preclinical models. Altogether, our results support clinical testing of bomedemstat in the setting of mCRPC.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
Pays : United States
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep. 2021;23(2):15. doi:10.1007/s11912-020-01003-9
Conteduca V, Oromendia C, Eng KW, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019;121:7‐18. doi:10.1016/j.ejca.2019.08.011
Kahl P, Gullotti L, Heukamp LC, et al. Androgen receptor coactivators lysine‐specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006;66(23):11341‐11347. doi:10.1158/0008-5472.CAN-06-1570
Sehrawat A, Gao L, Wang Y, et al. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci. 2018;115(18):E4179‐E4188. doi:10.1073/pnas.1719168115
Kumaraswamy A, Duan Z, Flores D, et al. LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function. JCI Insight. 2023;8(15):e167440. doi:10.1172/jci.insight.167440
Huang J, Sengupta R, Espejo AB, et al. p53 is regulated by the lysine demethylase LSD1. Nature. 2007;449(7158):105‐108. doi:10.1038/nature06092
Cho HS, Suzuki T, Dohmae N, et al. Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res. 2011;71(3):655‐660. doi:10.1158/0008-5472.CAN-10-2446
Noce B, Di Bello E, Fioravanti R, Mai A. LSD1 inhibitors for cancer treatment: focus on multi‐target agents and compounds in clinical trials. Front Pharmacol. 2023;14:1120911. doi:10.3389/fphar.2023.1120911
Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941‐953. doi:10.1016/j.cell.2004.12.012
Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol. 2006;13(6):563‐567. doi:10.1016/j.chembiol.2006.05.004
Schmidt DMZ, McCafferty DG. trans‐2‐Phenylcyclopropylamine Is a Mechanism‐Based Inactivator of the Histone Demethylase LSD1. Biochemistry. 2007;46(14):4408‐4416. doi:10.1021/bi0618621
Youdim MBH, Finberg JPM. New directions in monoamine oxidase A and B selective inhibitors and substrates. Biochem Pharmacol. 1991;41(2):155‐162. doi:10.1016/0006-2952(91)90471-G
Speranzini V, Rotili D, Ciossani G, et al. Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features. Sci Adv. 2016;2(9):e1601017. doi:10.1126/sciadv.1601017
Zhu Y, Dalrymple SL, Coleman I, et al. Role of androgen receptor splice variant‐7 (AR‐V7) in prostate cancer resistance to 2nd‐generation androgen receptor signaling inhibitors. Oncogene. 2020;39(45):6935‐6949. doi:10.1038/s41388-020-01479-6
Brennen WN, Nguyen H, Dalrymple SL, et al. Assessing angiogenic responses induced by primary human prostate stromal cells in a three‐dimensional fibrin matrix assay. Oncotarget. 2016;7(44):71298‐71308. doi:10.18632/oncotarget.11347
Isaacs JT, Antony L, Dalrymple SL, et al. Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2013;73(4):1386‐1399. doi:10.1158/0008-5472.CAN-12-2730
Isaacs JT, Pili R, Qian DZ, et al. Identification of ABR‐215050 as lead second generation quinoline‐3‐carboxamide anti‐angiogenic agent for the treatment of prostate cancer. Prostate. 2006;66(16):1768‐1778. doi:10.1002/pros.20509
Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, Isaacs JT. Low‐calcium serum‐free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res. 2006;66(17):8598‐8607. doi:10.1158/0008-5472.CAN-06-1228
Yang M, Culhane JC, Szewczuk LM, et al. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans‐2‐phenylcyclopropylamine. Biochemistry. 2007;46(27):8058‐8065. doi:10.1021/bi700664y
Sprüssel A, Schulte JH, Weber S, et al. Lysine‐specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia. 2012;26(9):2039‐2051. doi:10.1038/leu.2012.157
Mahiout S, Lindén J, Esteban J, et al. Toxicological characterisation of two novel selective aryl hydrocarbon receptor modulators in Sprague‐Dawley rats. Toxicol Appl Pharmacol. 2017;326:54‐65. doi:10.1016/j.taap.2017.04.020
Denison MS, Soshilov AA, He G, DeGroot DE, Zhao B. Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (Dioxin) receptor. Toxicol Sci. 2011;124(1):1‐22. doi:10.1093/toxsci/kfr218
Coleman IM, DeSarkar N, Morrissey C, et al. Therapeutic implications for intrinsic phenotype classification of metastatic castration‐resistant prostate cancer. Clin Cancer Res. 2022;28(14):3127‐3140. doi:10.1158/1078-0432.CCR-21-4289
Cejas P, Xie Y, Font‐Tello A, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021;12(1):5775. doi:10.1038/s41467-021-26042-z
Bluemn EG, Coleman IM, Lucas JM, et al. Androgen receptor pathway‐independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32(4):474‐489.e6. doi:10.1016/j.ccell.2017.09.003
Beltran H, Tomlins S, Aparicio A, et al. Aggressive variants of castration resistant prostate cancer. Clin Cancer Res. 2014;20(11):2846‐2850. doi:10.1158/1078-0432.CCR-13-3309
Rienhoff Jr., HY, Gill H. Bomedemstat as an investigative treatment for myeloproliferative neoplasms. Expert Opin Invest Drugs. 2023;32(10):879‐886. doi:10.1080/13543784.2023.2267980
Zisman E, Erport A, Kohanovsky E, et al. Platelet function recovery after cessation of aspirin: preliminary study of volunteers and surgical patients. Eur J Anaesthesiol. 2010;27(7):617‐623. doi:10.1097/EJA.0b013e328335b354
Li C, Hirsh J, Xie C, Johnston MA, Eikelboom JW. Reversal of the anti‐platelet effects of aspirin and clopidogrel. J Thromb Haemostasis. 2012;10(4):521‐528. doi:10.1111/j.1538-7836.2012.04641.x
Hollebecque A, Salvagni S, Plummer R, et al. Phase I study of lysine‐specific demethylase 1 inhibitor, CC‐90011, in patients with advanced solid tumors and relapsed/refractory non‐Hodgkin lymphoma. Clin Cancer Res. 2021;27(2):438‐446. doi:10.1158/1078-0432.CCR-20-2380